Asciminib
- Generic Name
- Asciminib
- Brand Names
- Scemblix
- Drug Type
- Small Molecule
- Chemical Formula
- C20H18ClF2N5O3
- CAS Number
- 1492952-76-7
- Unique Ingredient Identifier
- L1F3R18W77
- Background
Asciminib is a tyrosine kinase inhibitor (TKI) used in the treatment of chronic-phase Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). More specifically, it is an inhibitor of the ABL1 kinase activity of the BCR-ABL1 fusion protein which serves as a driver of CML proliferation in most patients with the disease. It has also shown benefit i...
- Indication
Asciminib is indicated for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase who have been previously treated with ≥2 tyrosine kinase inhibitors. It is also indicated in the treatment of Ph+ CML in adult patients with the T315I mutation.
- Associated Conditions
- Chronic Phase Chronic Myeloid Leukemia
- Associated Therapies
- -
Phase II Study of Asciminib for Second-line Treatment of Chronic Phase Chronic Myeloid Leukemia
- First Posted Date
- 2024-10-08
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT06629584
- Locations
- 🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Clinical Study of Asciminib in Previously Treated Indian Patients With Ph+ CML-CP Without T315I Mutation and in Patients With Ph+ CML-CP With T315I Mutation
- Conditions
- Interventions
- First Posted Date
- 2024-05-24
- Last Posted Date
- 2024-05-28
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 85
- Registration Number
- NCT06427811
PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML
- Conditions
- Interventions
- First Posted Date
- 2024-05-10
- Last Posted Date
- 2024-06-18
- Target Recruit Count
- 160
- Registration Number
- NCT06409936
A Study of Treatment-free Remission in Chronic Phase Chronic Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2024-04-16
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- Korean Society of Hematology
- Target Recruit Count
- 69
- Registration Number
- NCT06368414
Phase II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2024-03-13
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT06308588
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.
- First Posted Date
- 2024-02-01
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT06236724
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)
- Conditions
- Interventions
- First Posted Date
- 2022-07-13
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 571
- Registration Number
- NCT05456191
- Locations
- 🇺🇸
Rocky Mountain Cancer Centers, Boulder, Colorado, United States
🇺🇸Illinois Cancer Care, Peoria, Illinois, United States
🇺🇸Regions Hospital, Saint Paul, Minnesota, United States
Asciminib Used in Consolidation With Imatinib vs. Imatinib to Achieve TFR in CP-CML
- Conditions
- Interventions
- First Posted Date
- 2022-06-10
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- Sarit Assouline
- Target Recruit Count
- 164
- Registration Number
- NCT05413915
- Locations
- 🇨🇦
Hôpital Fleurimont - CHUS (CIUSSS Estrie), Sherbrooke, Quebec, Canada
🇨🇦Clinical Research Unit - Jewish General Hospital, Montreal, Quebec, Canada
🇨🇦Hôpital Maisonneuve-Rosemont (CIUSSS EMTL), Montréal, Quebec, Canada
Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia
- Conditions
- Interventions
- First Posted Date
- 2022-05-20
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 196
- Registration Number
- NCT05384587
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Lundquist Inst BioMed at Harbor, Torrance, California, United States
🇺🇸Rocky Mountain Cancer Centers, Boulder, Colorado, United States
Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase
- First Posted Date
- 2021-12-03
- Last Posted Date
- 2024-03-26
- Lead Sponsor
- Augusta University
- Target Recruit Count
- 8
- Registration Number
- NCT05143840
- Locations
- 🇺🇸
Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
🇺🇸Georgia Cancer Center at Augusta University, Augusta, Georgia, United States
🇺🇸Huntsman Cancer Institute, Salt Lake City, Utah, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.